Evaxion

Evaxion is a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies. The company utilizes its proprietary AI-Immunology platform to design personalized cancer vaccines and novel therapies for infectious diseases. Its lead oncology candidate, EVX-01, is a personalized peptide-based neoantigen vaccine currently in Phase 2 clinical trials for metastatic melanoma in combination with Keytruda. Evaxion's pipeline also includes programs targeting bacterial and viral pathogens, leveraging computational biology to identify optimal vaccine targets. By integrating artificial intelligence with deep immunological expertise, the company aims to provide highly specific and effective treatments for complex diseases.